The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study.
The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study.
复制标题
DOI：
10.1038/s41398-021-01770-4
复制
发表时间：
2022-01-10
影响因子：
6.8
通讯作者：
Higgs S
中科院分区：
文献类型：
--
作者：
Schneider E;Martin E;Rotshtein P;Qureshi KL;Chamberlain SR;Spetter MS;Dourish CT;Higgs S
二甲磺酸利右苯丙胺（LDX）是目前FDA批准用于治疗暴饮暴食症（BED）的唯一药物，但对LDX治疗BED疗效的行为机制知之甚少。我们采用随机、交叉、双盲、安慰剂对照的实验药物设计，研究了22名暴食症女性急性剂量LDX（50 mg）对行为和神经的影响。LDX降低了自我报告的食欲等级和面食和可口的饼干零食的摄入量。LDX还降低了意大利面的进食率，但没有降低饼干的进食率，并降低了用餐结束时对意大利面的自我报告的喜爱程度。当在功能磁共振成像扫描中观看食物图片时，LDX减少了丘脑的双侧活动。LDX增强了持续注意力，减少了连续执行任务中的冲动反应，但对情绪偏差或工作记忆没有影响。这些结果表明，观察到的LDX对食物摄入的影响（并暗示LDX在治疗BED中的疗效）可能与药物增强饱腹感、减少饱腹时食物相关的奖励反应和/或增加认知控制的作用有关。如果新型药物对食欲、奖赏和认知有广泛的影响，那么它们可能是最有效的。
Lisdexamfetamine dimesylate (LDX) is the only drug currently approved by the FDA for the treatment of Binge-Eating Disorder (BED), but little is known about the behavioural mechanisms that underpin the efficacy of LDX in treating BED. We examined the behavioural and neural effects of an acute dose of LDX (50 mg) in 22 women with binge-eating symptomatology using a randomised, crossover, double-blind, placebo-controlled experimental medicine design. LDX reduced self-reported appetite ratings and intake of both a pasta meal and a palatable cookie snack. LDX also decreased the eating rate of pasta but not of cookies and reduced self-reported liking ratings for pasta at the end of the meal. When viewing food pictures during an fMRI scan, LDX reduced activity bilaterally in the thalamus. LDX enhanced sustained attention and reduced impulsive responding in a continuous performance task but had no effect on emotional bias or working memory. These results suggest the observed effects of LDX on food intake (and by implication the efficacy of LDX in treating BED) may be related to the actions of the drug to enhance satiety, reduce food-related reward responding when full and/or increase cognitive control. Novel pharmacotherapies for BED might be most effective if they have a broad spectrum of effects on appetite, reward and cognition.
登录
查看更多内容
影响因子：
17.7
作者：
Harmer, Catherine J.;O'Sullivan, Ursula;Cowen, Philip J.
通讯作者：
Cowen, Philip J.
影响因子：
25.8
作者：
McElroy, Susan L.;Hudson, James I.;Gasior, Maria
通讯作者：
Gasior, Maria
影响因子：
3.4
作者：
Epperson, C. Neill;Shanmugan, Sheila;Brown, Thomas E.
通讯作者：
Brown, Thomas E.
影响因子：
4.8
作者：
Frith, CD;Kapur, N;Frackowiak, RSJ
通讯作者：
Frackowiak, RSJ
影响因子：
2.9
作者：
Gasior, Maria;Hudson, James;McElroy, Susan L.
通讯作者：
McElroy, Susan L.